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Abstract 
MAD1L1 is coiled-coil protein that binds to 
improperly attached kinetochrore, what results in 
recruitment and interaction with MAD2L1, 
activation of the mitotic checkpoint complex, 
inhibition of the anaphase-promoting 
complex/cyclosome and cell cycle arrest. During 
interphase, MAD1L1 regulates mitosis entrance at 
nuclear pore complexes (MAD2L1-dependent 
mechanism) and Golgi apparatus-related functions 
(MAD2L1-independent mechanism). Alterations in 
MAD1L1 are associated with chromosomal 
instability, aneuploidy, and cancer susceptibility. 
The present review contains data on MAD1L1 DNA, 
RNA, protein encoded and function. 
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The entire MAD1L1 gene is approximately 417.1 Kb 
(start: 1815792 and end: 2232971 bp; orientation: 
Minus strand). The MAD1L1 gene encodes for 6 
transcript variants. The transcript variant 1 (start: 
1815792 and end: 2232948 bp; orientation: Minus 
strand; 19 exons; mRNA: 2754 bp) is the longest 
transcript variant. Transcript variant 2 (mRNA: 2717 
bp), transcript variant 3 (mRNA: 2714 bp) and 
transcript variant 4 (mRNA: 2538 bp) differs in the 
5' UTR compared to transcript variant 1. The 
transcript variants 1-4 encode the protein isoform a 
(718 aa protein). The transcript variant 5 (mRNA: 
2376 bp; 17 exons) lacks some exons in the 5' UTR 
and displays an alternate exon in the 5' coding 
region, what results in an alternative start codon, 
frameshift, and a shorter and distinct protein 
(isoform b; 626 aa). The transcript variant 6 is the 
shortest transcript variant (start: 1815792 and end: 
1940550 bp; 4 exons; mRNA: 1318 bp), it displays 
an alternative 5'-terminal exon, uses an in-frame start 
codon and encodes the protein isoform c (174 aa). 
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Figure 1. MAD1L1 protein structure.  MAD1L1 protein contains a MAD1L1 oligomerization domain, 
MAD2L1-binding domain and RLK motif (Arg-Leu-Lys; essential for BUB1 and BUB3 interactions). This 
figure was adapted from Canman et al., 2002; Sironi et al., 2002. 
 
Description 
MAD1L1 is a 718-residue coiled-coil protein that 
interacts with MAD2L1, and is composite of a 
MAD1L1 oligomerization domain, MAD2L1-
binding domain and RLK motif (Arg-Leu-Lys; 
essential for BUB1 and BUB3 interactions) 
(Canman et al., 2002; Sironi et al., 2002) (Figure 1). 
MAD1L1-MAD2L1 complexes form a tetramer-like 
structure due to the parallel intermolecular coiled-
coil between α 1 helices from different MAD1L1 




During mitosis, MAD1L1 is localized 
predominantly at unattached kinetochore. During 
interphase, MAD1L1 is localized in perinuclear 
region, nuclear pore complex, centrosome and Golgi 
apparatus (Campbell et al., 2001; Rodriguez-Bravo 
et al., 2014; Wan et al., 2014). 
 
Figure 2. MAD1L1 functions in spindle assembly checkpoint. (Upper panel) During mitosis, MAD1L1 binds 
to improperly attached kinetochrore, what results in recruitment and interaction with MAD2L1, and activation of 
the mitotic checkpoint complex (MCC). The MCC inhibits the anaphase-promoting complex/cyclosome 
(APC/C) and leads to cell cycle arrest. (Lower panel) In absence of unattached kinetochores, 
MAD1L1/MAD2L1 complex is not recruited, what results in chromosome segregation during anaphase. This 
figure was created using Servier Medical Art tools (http://www.servier.com). 
 
Function 
MAD1L1 belongs to the assembly control of the 
mitotic spindle, which acts as a component capable 
of blocking the onset of the anaphase if the 
chromosomes are not correctly aligned on the 
metaphase plate (Hardwick and Murray, 1995). The 
MAD1L1 protein has approximately 83 kDa and 
interacts with other proteins, such as MAD2L1, to 
perform its functions (Campbell et al., 2001; Wright 
et al., 2017). The complex MAD1L1/MAD2L1 
binds to improperly attached kinetochrore, induces 
MAD1L1 phosphorylation by MPS1, and acts as an 
anchor for the formation of other protein 
interactions, including MAD2L1-CDC20 complex. 
The molecular events upon MAD1L1 and 
unattached kinetochores interaction lead to the 
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formation of mitotic checkpoint complex (MCC), 
inhibition of anaphase-promoting 
complex/cyclosome (APC/C), and cell cycle arrest 
(Reviewed by Schuyler et al., 2012 and London and 
Biggins, 2014) (Figure 2). 
Rodriguez-Bravo and colleagues (Rodriguez-Bravo 
et al., 2014) reported that the MAD1L1-MAD2L1 
complex anchored to the nuclear pore complexes 
emits an inhibitory signal that limits the speed of the 
mitosis, facilitating corrections of possible errors, 
which would avoid a cell cycle arrest. Alterations in 
MAD1L1 are associated with chromosomal 
instability and aneuploidy (Avram et al., 2014; 
Tsukasaki et al., 2001). 
Wan and colleagues (Wan et al., 2014) reported an 
elegant mechanistic study that described the non-
related spindle assembly checkpoint and MAD2L1 
independent functions for MADlL1. During 
interphase, MAD1L1 is localized in the Golgi 
apparatus, and participates in integrin secretion, 
adhesion, mobility, cell migration and PTK2 (FAK) 
signaling pathway (Wan et al., 2014). 
Homology 
MAD1L1 has a high homology among different 
species (Table 1). 
Table 1. Comparative identity of human MAD1L1 
with other species 
% Identity for: 
Homo sapiens 
MAD1L1 
Symbol Protein DNA 
vs. P. troglodytes 
MAD1L1 99.4 99.4 
vs. M. mulatta 
MAD1L1 98.4 96.7 
vs. C. lupus 
MAD1L1 84.0 84.3 
vs. B. taurus 
MAD1L1 84.7 85.4 
vs. M. musculus 
Mad1l1 81.4 81.4 
vs. R. norvegicus 
Mad1l1 83.4 82.3 
vs. G. gallus 
MAD1L1 70.0 73.2 
vs. X. tropicalis 
mad1l1 63.0 65.0 
vs. D. rerio 
mad1l1 54.1 60.6 
vs. D. melanogaster 
Mad1 28.9 45.0 
vs. A. gambiae 





Recurrent mutations in the MAD1L1 gene are rare, 
and 153 missense substitution, 69 synonymous 
substitution, 8 nonsense substitution, 1 frameshift 
insertion and 8 frameshift deletion mutations are 
reported in COSMIC (Catalogue of Somatic 
Mutations in Cancer; 
http://cancer.sanger.ac.uk/cancergenome/projects/c
osmic). Similar findings were reported in cBioPortal 
(http://www.cbioportal.org), which includes 41824 
cancer samples: somatic mutation frequency in 
MAD1L1 was 0.5% (195 mutations, being 166 
missense and 29 truncating mutations). Analyzing 
together, mutation, amplification, deep deletion and 
multiple alterations, the total of cancer samples with 
any type of alteration was 570 (1.4%). 
Implicated in 
Colorectal cancer 
In HCT116 colorectal carcinoma cell line, MAD1L1 
silencing disturbed the spindle checkpoint and 
leaded to aneuploidy (Kienitz et al., 2005). On the 
other hand, the induction of MAD1L1 
overexpression resulted in aberrant mitotic timing, 
aneuploidy and resistance to apoptosis in DLD1 
cells, a chromosomally stable colorectal cancer cell 
line (Ryan et al., 2012). The presence of the 
genotype His/His for the MAD1L1 Arg558His 
(rs1801368) polymorphism was associated with 
increased risk for colorectal cancer, using a 
dominant model, in a Chinese cohort (Zhong et al., 
2015). 
Liver cancer 
MAD1L1 expression was observed in 70% of new 
early diagnosed cases and 30% of recurrence 
hepatocellular carcinoma patients, suggesting that 
the loss of MAD1L1 may be involved in disease 
progression (Nam et al., 2008). MAD1L1 was found 
to be methylated in 50% of hepatocellular carcinoma 
cell lines and primary samples tested. Low MAD1L1 
methylation was associated with increased tumor 
size and recurrence in hepatocellular carcinoma 
patients (Cui et al., 2016). Sze and colleagues (Sze 
et al., 2008) identified a novel splicing variant of 
MAD1L1, which was found overexpressed in 24% 
of hepatocellular carcinoma samples. Using 
functional studies, the authors showed that the 
ectopic expression of this novel splicing variant 
results mitotic checkpoint impairment and 
aneuploidy hematoma cell lines (Sze et al., 2008). 
Lung cancer 
An initial screening for MAD1L1 mutations in 49 
lung cancer patients found one sample with somatic 
mutation (T299A) and 1 sample with a possible 
germline mutation (R556H). Coe and colleagues 
(Coe et al., 2006) reported that the gain of a region 
on 7p22.3, including 350 Kbp fragment centered at 
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MAD1L1, was observed in 13 out of 14 small-cell 
lung cancers (H187, H378, H889, H1607, H1672, 
H2107, H2141, H2171, HCC33, H82, H289, H524, 
H526, and H841) and in none of normal (BL289, 
BL1607, BL1672, BL2107, BL2141, and BL2171) 
cell lines analyzed. Using immunohistochemistry 
analysis, MAD1L1 positive expression was found to 
be higher in lymph node metastasis and primary 
tumor samples from small-cell lung cancer patients 
compared to adjacent non-cancerous tissue samples 
(Li et al., 2016). In small-cell lung cancer, the 
presence of MAD1L1 expression was associated 
with advanced stage of the disease, increased tumor 
size, higher incidence of lymph node metastasis and 
recurrence, and it was an independent predictor of 
poor survival outcomes (Li et al., 2016). In a cohort 
containing 1000 lung cancer patients and 1000 
healthy donors, the genotype His/His for the 
MAD1L1 Arg558His (rs1801368) polymorphism 
was associated with lung cancer risk (Guo et al., 
2010). 
Breast cancer 
MAD1L1 was frequently higher expressed in tumor 
compared to non-malignant or normal breast cancer 
samples (Ryan et al., 2012; Yuan et al., 2006) and 
increased levels of MAD1L1 were associated with 
poor survival outcomes (Ryan et al., 2012). 
Conversely, high cytoplasm expression of MAD1L1 
was observed in both, normal and breast cancer 
samples. However, nuclear MAD1L1 expression 
was significantly more frequent in breast cancer 
(28%) than normal (2%) samples (Sun et al., 2013). 
In the same study, the author also reported that 
nuclear MAD1L1 was associated with lower age 
onset, increased tumor size, higher tumor stage, 
presence of TP53  mutations and disease subtypes, 
and positive nuclear MAD1L1 was an independent 
predictor of worse clinical outcomes in breast cancer 
patients (Sun et al., 2013). In MCF-7, a breast cancer 
cell line, siRNA-mediate MAD1L1 silencing 
increased migration and reduced E-cadherin 
expression (Chen et al., 2012). 
Gastric cancer 
Using proteomic approaches in primary samples of 
gastric carcinomas and its corresponding non-
cancerous gastric mucosa, MAD1L1 was identified 
as lower expressed in gastric carcinoma samples 
(Nishigaki et al., 2005). Later, the same research 
group reported that MAD1L1 was downregulated in 
47% of gastric adenomas and 60% of gastric 
carcinomas, and advanced carcinomas presented 
lower levels compared to early carcinomas (Osaki et 
al., 2007). In MKN-1, a gastric carcinoma cell line, 
ectopic MAD1L1 expression reduced proliferation 
and cell cycle progression (Osaki et al., 2007). 
Head and neck/oral cancer 
Bhattacharjya and colleagues (Bhattacharjya et al., 
2013) described a negative correlation between 
MAD1L1 and MIR125B, a miRNA associated with 
the suppression of malignant phenotype, in primary 
samples from head and neck/oral cancer patients. 
Recently, the t(5;7)(q34;p22) with fusion gene 
RARS /MAD1L1 was identified in 10% of 
nasopharyngeal carcinoma and head and neck cancer 
samples (Zhong et al., 2017). Functional studies 
indicated that RARS/MAD1L1 enhances cell 
proliferation, clonogenicity and tumorigenicity 
(Zhong et al., 2017). 
Kidney cancer 
Using quantitative PCR, Pinto and colleagues (Pinto 
et al., 2007) reported that MAD1L1 is expressed at 
low levels in chromophobe renal cell carcinoma 
compared to normal kidney samples. The authors 
also reported that MAD1L1 mRNA levels are 
reduced in samples from clear cell kidney carcinoma 
compared to healthy donors (Pinto et al., 2008). 
Ovarian cancer 
MAD1L1 mRNA levels were found to be 
downregulated in chemoresistant compared to 
chemosensitive epithelial ovarian tumors (Ju et al., 
2009). Santibáñez and colleagues (Santibanez et al., 
2013) reported that the genotype AA for the 
polymorphism MAD1L1 G1673A (rs1801368) was 
associated with advanced epithelial ovarian cancer 
risk and that the allele A was significantly associated 
with increased aneuploid cells in ovarian tumor 
samples. Functional studies indicate that the AA 
genotype is also associated with higher frequency of 
micronuclei and nondisjunction events (Santibanez 
et al., 2013). 
Glioma 
MAD1L1 gene expression was increased in grade IV 
gliomas compared to normal brain tissues (Bie et al., 
2011). 
Leukemia 
MAD1L1 is highly expressed in leukemia cell lines 
(Jurkat and K562) compared to normal peripheral 
blood mononuclear cells. In normal leukocytes, cell 
proliferation induction by PHA plus IL2 increased 
MAD1L1 expression (Iwanaga and Jeang, 2002). 
Lymphoma 
Using proteomics and transcriptomics approaches, 
MAD1L1 was higher expressed in follicular 
lymphoma - compared to mantle cell lymphoma -
derived cell lines (Weinkauf et al., 2007) . 
Myeloproliferative neoplasm 
Using whole-genome sequencing, Sloma and 
colleagues (Sloma et al., 2017) reported the presence 
of R270W heterozygous mutation in MAD1L1 gene 
in unusual case of BCR / ABL1 - and JAK2 V617F -
positive chronic myeloid leukemia during chronic 
phase and accelerate phase. However, upon blast 
crisis evolution, the MAD1L1R270W mutation was 
found in homozygosis. The authors also reported the 
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MAD1L1R270W mutation in an additional case of 
JAK2V617F -positive essential thrombocythemia (1 
out of 101 myeloproliferative neoplasm cases tested) 
(Sloma et al., 2017). 
Prostate cancer 
MAD1L1 heterozygous mutations were found in 2 
out of 7 prostate cancer cell lines (LNCaP: 
MAD1L1R556C, and LPC4: MAD1L1R359Q) and 2 out 
of 33 (MAD1L1R59C and a stop codon at 318) 
primary samples from prostate carcinoma patients 
(Tsukasaki et al., 2001). 
Testicular germ cell tumor 
Using a large cohort of testicular germ cell tumor and 
healthy donors, and genome-wide association study 
as approach, Chung and colleagues (Chung et al., 
2013) identified that the SNP rs12699477 of 
MAD1L1 was associated with testicular germ cell 
tumor risk. 
To be noted 
Initially, the MAD1L1 (mitotic arrest deficient 1 like 
1) gene located in chromosome 7p22.3 was known 
as MAD1. However, the MXD1 (MAX dimerization 
protein 1) gene located in chromosome 2p13.3 was 
also known as MAD1, what generated confusion in 
the literature. Therefore, it is recommended that the 
HUGO nomenclature should be used in current 
studies involving both genes to avoid 
misinterpretation.  
 
Data from the crossing between MAD1L1+/- mice 
suggest that total deletion of the gene resulted in 
embryonic lethality (Iwanaga et al., 2007). MAD1L1 
haploinsufficient mice had a higher incidence of 
cancer, including hepatocellular carcinoma, 
rhabdomyosarcoma, osteosarcoma, 
hemangiosarcoma, uterine sarcoma and lung cancer. 
In addition, treatment with antineoplastic drug, 
vincristine, significantly increased tumor 
development in MAD1L1+/- mice, but not in 
MAD1L1+/+ mice, indicating that MAD1L1 plays a 
relevant role in genomic stability and carcinogenesis 
(Iwanaga et al., 2007; Rao et al., 2009).  
 
Recently, a genetic variation of MAD1L1 gene 
(rs1801368) has been identified as a potential 
candidate for contributing to mosaic loss of 
chromosome Y and cancer susceptibility in large 
cohorts (Wright et al., 2017). 
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